Robin Feldman

Robin Feldman is a law professor and scholar who focuses on intellectual property, pharmaceutical regulation, and healthcare policy. She holds the Arthur J. Goldberg Distinguished Professor of Law position at UC Hastings College of the Law and directs the Institute for Innovation Law. Feldman's research examines the intersection of patent law and the pharmaceutical industry. Her work analyzes how drug companies use legal strategies to extend patent protection and delay generic competition. She has testified before Congress and regulatory agencies on pharmaceutical patent issues. Her scholarship addresses anticompetitive practices in the drug industry, including patent thickets, product hopping, and pay-for-delay agreements. Feldman's analysis draws on empirical data to examine how these practices affect drug prices and access to medications. She has published extensively in law reviews and policy journals on these topics.

Readers find Feldman's analysis of pharmaceutical patent manipulation thorough and data-driven. Many appreciate her clear explanations of complex legal and regulatory concepts that make the material accessible to non-lawyers. Readers note that she provides concrete examples of how drug companies exploit patent loopholes to maintain market exclusivity. Several readers praise her use of empirical evidence to support arguments about anticompetitive behavior in the pharmaceutical industry. They find her documentation of specific cases and practices convincing. Readers value her policy recommendations for addressing patent abuse. Some readers find the technical legal content dense and challenging to follow despite her efforts at clarity. A few note that the focus on legal mechanisms can overshadow broader healthcare policy considerations. Some readers wanted more discussion of potential solutions beyond regulatory reform.